Fluticasone Propionate Nasal Spray

Fluticaso n-aerosol, activated respiration – introduction, side effects, almost everything else

Fluticasone is used for certain tumors in the nose ( nasal polyps). It belongs to a class of drugs called corticosteroids. Fluticasone works by reducing swelling (inflammation) of the nasal polyps. This helps relieve symptoms such as problematic nasal

How to use Fluticasone Aerosol, Activated Breathing

Read the package leaflet and package leaflet, if available from your pharmacist, before using this medication and each time you get a new dose. If you have any questions, ask your doctor or pharmacist.

Use this drink in the nose as prescribed by your doctor, usually twice a day. Do. not spray In the eyes or mouth. Damage mouth carefully before bringing this product. Follow the instructions on the pump. the spray pump when you use it for the the spray for the first time or if you have not used it for more than 7 days. When filling the pump, make sure it to spray away from your face.

To use the spray Remove the protective cap and shake the package well. Tilt your head slightly forward and carefully place the applicator into your nostrils. the nasal Bring the applicator into your nostrils. Place the mouthpiece in your mouth. Blow into the mouthpiece. Blow into the mouthpiece and press the bottle to spray medicine in your nostrils. Turn off not spray directly on the middle wall of your nose. nasal (Partition). Do not close your other nostril and do not breathe through your nose while the medicine is being sprayed. Repeat with the other nostril.

Dosage is based on your welfare status and response to healing. Use this drink regularly to get the most benefit. Remember, use daily at the same time. Do not increase dosage.

Keep track of how much of sprays used from the bottle. Throw away the bottle after using a number of sprays It is on the manufacturer’s package.

This drink will not work immediately. It may take days, months or more to get all the excellent properties of this product.

Tell your own doctor if your situation does not get better or worse.

Side Effects

Bleeding of the nose or dryness of the nose may occur. If one of these effects persists or gets worse, tell your doctor or pharmacist quickly.

Remember that this medication is prescribed because your doctor has determined that the benefit for you is greater than the risk of side effects. Almost everyone who uses this medication has no serious side effects.

Tell your doctor immediately if you have any serious side effects such as nose pain or ulcers, white spots in the nose/mouth, or painful swallowing.

In rare cases, corticosteroids administered into the nose may be absorbed into the bloodstream. This can cause very large doses of corticosteroid side effects. These side effects are probably more likely in children and in people who have been using this drug for a long time and at high doses. Tell your doctor immediately if any of the following side effects occur: abnormal/extreme fatigue, weight loss, headache, swelling/feet, excessive thirst/urination, difficulty seeing.

Very responsible allergic reactions to this product are rare. Nevertheless, seek medical help if you notice signs of a severe allergic reaction, such as skin rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, creaky breathing/ difficulty breathing.

This is not an absolute list of possible side effects. If you notice any of the other effects listed above, contact your physician or pharmacist.

In the U.S., call your doctor for medical advice regarding side effects at 1-800-FDA-1088 or www. You can report side effects to the FDA at FDA.FDA.Gov/Medwatch.

For medical advice on side effects, call your Canadian physician at 1-866-234-2345 to report side effects to Health Canada.

Precautions.

Tell your doctor or pharmacist before using this medicine or if you are allergic to this medicine or have different allergies. to fluticasone or if you have other allergies. This product contains inactive ingredients that may cause allergic reactions or other problems. Consult your pharmacist for further information.

Inform your doctor or pharmacist of your medical condition, especially eye dilemmas (glaucoma, cataracts, etc.), infections (including consumption, herpes eye disease), recent nasal problems (trauma, ulcers, surgery, etc.), liver disease.

Avoid contact with people with infectious diseases may spread others (e.g., chickenpox, measles, influenza). Consult your physician about infections or for more information.

In rare cases, long-term administration of corticosteroids can make it difficult for the body to respond to material stress. Tell your doctor or dentist that you are using this medication or have used it before undergoing surgery or other necessary treatment or in the event of a serious illness or injury.

Tell your doctor or dentist about all products you use (including prescription, non-prescription resources, and herbal products) to operate.

Although it is virtually impossible, this medication, when used long term, can slow the baby’s growth. Contact your doctor regularly to check the length of your baby.

During pregnancy, this medication should be used only when clearly needed. Talk to your doctor about the risks and benefits.

It is not known if this medication will convert to breast milk. Consult your physician before breastfeeding.

Description.

Fluticasone propionate The strong component of the USP of Fluticasone Propionate Nasspray is supposed to be a synthetic corticosteroid with the chemical name (fluorethyl) 6α, 9-difluoro-11β-dihydroxy-16α-methyl – methyl – lordroxy-droxy-16α-mityl-3-oxoandrost It is assumed to be a synthetic corticosteroid wit h-1, 4-dihydroxy-16α-methyl-3-oxoandrost-1, 417β-carbothioat, 17 propionic acid, and comes chemical structure: S

Fluticasone propionate snow-white powder with a molecular weight of 500.6 and an empirical formula of C h f o . It is literally insoluble in water, dissolves well in dimethyl sulfoxide and dimethylformamide, and insoluble in formaldehyde and 95% ethanol.25 31 3 5

Fluticasone Propionate Nasal Spray, USP, 50 mc g-microfijne aqua suspension fluticasone propionate For local administration the nasal Mucous membrane spray Pump. Fluticasone – Propionate Nasal Spray, USP still contains benzalkonium chloride (02% wt./MAS.), carboxymethylcellulose, dextrose, microcrystalline cellulose, phenylethyl-ALD. 6. 8.

The pump should be filled for the first introduction or for a period of non-use (more than 1 week). After priming for the first time (6 runs), each exposure should be 50 µg. of fluticasone propionate With a 100 mg formulation. the nasal adapter. every bottle of 16 g fluticasone propionate spray, USP guarantees 120 doses. sprays . After 120 metered sprays , the amount of fluticasone propionate Delivery for insert exposure cannot be alternated and must be discarded.

Clinical Pharmacology

Mechanism:

Fluticasone propionate Synthesized tricyclic corticosteroid with anti-inflammatory effects. In vitro dosimetry studies on cloned human glucocorticoid receptor system with gene binding and expression showed 50% response at concentrations of 1, 25, 0 and 17 nm. fluticasone. propionate wash 3 to 5 times more potent than dexamethasone in these analyses. Data from the Mackenzie vasoconstriction assay in people still support his strong glucocorticoid potency.

In a research paper on symptoms, fluticasone propionate power like progesterone, which appears to be a natural hormone. Their clinical significance is unclear, to say the least, as a result of low plasma levels (see Pharmacokinetics.

Exact device. fluticasone propionate Their effect on the signs of allergic rhinitis is unknown. Corticosteroids have been shown to have broad effects on many cell types involved in inflammation (fertilizer cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (histamine, eicosanoids, leukotrienes, cytokines, etc.). Fluticasone propionate nasal spray, USP, in 7 studies decreased in ripe fluticasone nasal mucosal eosinophilia in 66% of patients (35% on placebo) and 39% of patients (28% on placebo). The unclear relationship between these findings and long-term symptom relief is unknown.

As with other corticosteroids, nasal spray USP of fluticasone propionate is considered a means without specific effect on allergic symptoms. Reduction in nasal In some patients, symptoms have been observed 12 hours after the first treatment with fluticasone propionate nasal spray, USP. A slight benefit may be achieved only after a few days. Literally, this means, for example, that when corticosteroids are stopped, symptoms return only after a few days.

Pharmacokinetics

Absorption

The activity of fluticasone propionate nasal spray, USP, is supported by the parent product. fluticasone propionate Field calculations show that fluticasone propionate To be delivered via the nasal route contains an unqualified bioavailability of less than 2% on average. Then, intranasal cure in patients with allergic rhinitis in the direction of 3 months, fluticasone propionate Plasma levels were only above detection (50 pg/ml) when the correct dose was exceeded, and only in random samples with low plasma levels. Due to the low bioavailability via the intranasal route, the majority of pharmacokinetic data were obtained through other routes of administration. Studies on the introduction of oral doses of radioactive products are, fluticasone propionate highly extracted from plasma and absorption is low; bioavailability of PEAD is of little importance, and a huge group of circulating radioactivity is supplied by an inactive metabolite

Distribution

After intravenous administration, the first stages of disposition are for fluticasone propionate fast and consistent with the highest lipid solubility and tissue binding. The variance size averaged 4.2 L/kg.

The percentage of fluticasone propionate Binding to humane plasma proteins averaged 91% without trivial concentrations of Fluticasone propionate Weakly and reversibly binds to red blood cells, smoothing the balance between red blood cells and plasma. Fluticasone. propionate Do not bind to human transcortin.

Metabolism

Total blood statement of fluticasone propionate High (averaging 1093 ml/min), with renal clearance less than 0.02% of total volume. The only circulating metabolite found in humans is a derivative of 17β carbonate. of fluticasone propionate It is produced by the cytochrome P450 3A4 route. This inactive metabolite had the lowest affinity (about 1/2000) of the original drug for the glucocorticoid receptor for the glucocorticoid receptor in human non-energetic cytosol in animal studies (about 1/2000). No other metabolites have been identified in vitro due to the introduction of cultivated human hepatic chain in humans.

Elimination.

After intravenous administration. fluticasone propionate Polyexponential kinetics were shown, with a final elimination half-life of approximately 7 or 8 hours. Less than 5% of the oral dose marked by radioisotopes is excreted in the urine as metabolites, with the remainder excreted in the feces as initial products and metabolites.

Special Populations

Fluticasone Propionate Nasal Spray (USP) has not been studied in specific populations and there are few gender-specific pharmacokinetic data.

Drug Interactions

Fluticasone propionate Substrate for cytochrome P450 3A4. Concurrent administration of fluticasone propionate Ritonavir, a very potent cytochrome P450 3A4 inhibitor, is also not recommended based on a crossover study of drug interactions in a roll of 18 healthy subjects with repeated use. Fluticasone propionate aqueous nasal spray (200 mcg once daily) was administered concurrently with ritonavir (100 mg twice daily) in the 7-day direction. Plasma fluticasone propionate concentration fluticasone propionate aqueous nasal spray was just not detectable.

Caution should be exercised in the concurrent use of other potent cytochrome P450 3A4 inhibitors. fluticasone propionate . In a pharmacological interaction study, the concurrent use of oral was inhaled fluticasone propionate (1000 mcg) and ketoconazole (200 mg once daily) elevated fluticasone propionate exposure from cortisol and decreased plasma AUC did not affect urinary cortisol excretion.

Different interaction studies using multiple doses of pharmaceutical substances resulted in simultaneous use of oral inhalation resources fluticasone propionate (500 mcg twice daily) and erythromycin (333 mg three times daily), fluticasone propionate pharmacokinetics.

Pharmacodynamics

In a study to evaluate the systemic and area effects of fluticasone propionate nasospray USP on signs of allergic rhinitis, superior quality of comparable blood product values were carried out by fluticasone propionate nasospray, USP, and oral spray. fluticasone propionate Comparison. The dose used was 200 µg fluticasone propionate nasal spray, USP, the nasal spray (plus oral placebo) per vehicle (plus oral placebo) per day for 14 days and 5 mg. fluticasone propionate (plus nasal spray (plus oral placebo) per day for 14 days. Plasma levels were undetectable in most patients after nasal administration, but lower in most patients after oral administration; USP’s fluticasone propionate spray was more effective than the oral formulation in reducing allergic rhinitis. fluticasone propionate or the nasal Resource. This study suggested that the therapeutic effect of USP, a nasal spray of fluticasone propionate, may be related to its live effect. of fluticasone propionate .

In another study, the systemic effects of the fluticasone propionate nasal spray USP on the hypothalamic paralytic axis (HPA) axis are still being investigated in allergic patients. Fluticasone Propionate Nasal Spray, USP, which is 400 mcg once a day or twice a day, was compared to placebo or oral prednisone 7, 5 or 15 mg daily Info. FluticasonPropionate Nasal Spray, USP, at each dose for 4 months and did not affect the adrenal response to cosyntropine removal at 6 hours, but both doses of oral prednisone significantly reduced the response to cosyntropine.

CLINICAL EXAMINATIONS

In a collaborative assignment, 13 randomized, double-blind, multichamber, placebo-controlled clinical examinations were conducted in U.S. adult and pediatric patients (4 years and older) for continued use of fluticasone propionate nasospray. USP in patients with elimination or long-term allergic rhinitis. Checks included 2633 adults (1439 males and 1194 females) with an average age of 37 years (18-79). Together, 440 adolescents (405 boys and 35 girls), mean age 14 years (12-17 years) and 500 boys (325 boys and 175 girls), mean age 9 years (4-11 years) were studied. The racial distribution was 89% white, 4% dark, and 7% other. These checks calculated the number of consecutive nasal property scores (TNS), including nasal root nasal obstruction, and sneezing, and nasal itching in popular allergy patients treated for 2 to 24 months; in subjects who received USP’s fluticasone propionate spray, the reduction in TNS was considerably greater than in those who received placebo. Favorable nasal mucosa and eosinophilia were still reduced at the end of the healing process in the adult test. However, the clinical significance of this reduction is unclear.

There was virtually no significant difference between fluticasone propionate this, and irrespective of this, it has been administered as a single dose of 200 mcg at a time (two 50 mcgs sprays each nostril) or 100 mcg (one 50 mcg spray (one of two nostrils) twice daily in six clinical studies. Clinical studies found no clear dose response. In one study, a dose of 200 mcg/day was slightly more effective than 50 mcg/day during the first few days of treatment. Thereafter, no differences were observed.

Two randomized, double-blind, multiblind, placebo-controlled parallel group studies of 28 days involved 732 patients (243 were 12 years of age or older for “need” testing). Patients with seasonal allergic rhinitis. Patients were instructed to take their creative drug only on days when they felt they needed to keep their symptoms under control but not exceed the dose. 2 sprays at all nostrils at any time, but only once per day. If the average dose of the research tool was administered on 75% or less of the study days, the “as needed” administration was defined as prospective. Average administration of research resources varied from 57% to 70% of study days for all treatment groups. The study showed a fairly large reduction in TNSS (total of of nasal Concealed nose, nasal root, sneezing, and nasal itching) fluticasone propionate nasal spray, USP, 200 µg vs. placebo. Conditional differences in manipulation in use according to need and intermittent doses were not studied.

Three randomized, double-blind, placebo-controlled, parallel-group studies, which served 1191 patients, were conducted to investigate the continued use of fluticasone propionate nasal spray (USP) in patients with nonallergic rhinitis throughout the year. These studies took into account TNS as assessed by patients ( nasal obstruction, nas congestion, nasal root) in one study in patients who underwent healing of doubleitis for 28 days and in three studies in the direction of finding 6 months of healing. Two of these studies showed that patients who received fluticasone propionate nasal spray (USP) at a dose of 100 mcg twice daily had a statistically significant reduction in TNSS compared to patients who acquired carrier.

Individualized Dosing

Patients should apply nasal sprays of fluticasone propionate (USP) at systematic intervals to achieve reasonable efficacy.

Adult patients can start with 200 mcg once daily (two doses of 50 mcg). sprays day in one of the two nostrils). another dosing schedule of 200 mcg/day can be delivered at 100 mcg twice a day (50 mcg once a day). spray (twice a day in all nostrils).

Individual patients experience varying times to the beginning and different degrees of symptom relief. Four randomized, double-blocked, placebo-controlled studies involving parallel groups with allergic rhinitis and two studies involving patients in an outdoor “park” setting (Park Study) have shown that symptoms in those treated compared placebo decrease after 12 hours. in nasal Symptoms in treated persons have been shown to appear USP 12 hours after healing with a dose of fluticasone propionate 200 mcg nasal spray compared to placebo. The maximum effect may take several days. Patients with corresponding permanent implementation have every opportunity to maintain (after 4-7 days) up to 100 mcg/day (1 spray a day per day) in all nostrils.

In some patients (12 years and older) with seasonal allergic rhinitis, the introduction of fluticasone propionate nasal spray, USP (200 mcg per day or less) is effective for symptom control if needed (see) Better symptom control can be achieved with planned, continuous infusions. The efficacy of fluticasone propionate spray, USP has not been studied in pediatric patients younger than 12 years with seasonal allergic rhinitis or in patients with long-term allergic or non-allergic rhinitis. Clinical Examination

Pediatric patients (4 years and older) should start with 100 mcg. (1 spray (daily in all nostrils). treatment with 200 mcg (2 sprays Once a day in all nostrils or 1 spray (twice daily in all nostrils), should be reserved for pediatric patients who do not respond adequately to 100 mcg per day. After adequate control is reached, the dose should be reduced to 100 mcg (1 spray (all nostrils) per day.

The maximum total daily dose cannot exceed 100 mcg in each nostril. 2 sprays All nostrils (total dose, 200 µg/day). There is little evidence that exceeding the correct dose is more effective.

Indications and Use

Fluticasone Propionate Nasospray, USP is indicated for the administration of the nasal Seasonal and long-term symptoms of allergic rhinitis in adult and pediatric patients 4 years of age and older.

The safety and efficacy of fluticasone propionate nasal spray, USP, in children younger than 4 years of age have not been adequately studied.

Contraindications.

Fluticasonpropionate Nasal Spray, USP is contraindicated in patients with hypersensitivity to one of the ingredients.

Warning.

Replacement of systemic corticosteroids with topical corticosteroids may be accompanied by adrenal injury symptoms and, in addition, withdrawal symptoms such as arthralgia, myalgia, nodule formation, and depression may occur in some patients. Patients previously treated long-term with systemic corticosteroids and being switched to topical corticosteroids should be closely monitored for the presence of acute adrenal insufficiency in response to stress. In patients with asthma or other clinical conditions requiring long-term treatment with systemic corticosteroids, very rapid reduction of systemic corticosteroids may cause mild exacerbation of symptoms.

Concurrent administration of nasal corticosteroids and other inhaled corticosteroids may increase the risk of symptoms or signs of cortical hyperintensities and/or HPA axis depression.

Drug interaction studies in healthy subjects have shown that ritonavir (a very effective cytochrome P450 3A4 inhibitor) has the potential to substantially increase plasma activity. fluticasone propionate effect resulting in a significant decrease in serum cortisol concentrations (see EN). During post-marketing use, clinically significant drug interactions have been reported in patients treated with fluticasone propionate ritonavir actually cause systemic corticosteroid effects such as Cushing’s syndrome and adrenal suppression. Concurrent administration of of fluticasone propionate ritonavir is therefore not recommended unless the benefit to the patient outweighs the risk of systemic corticosteroid side effects. Clinical Pharmacology: Drug Interactions Precautions: Drug Interactions

People who use drugs that destroy the immune system are more susceptible to infections than healthy people. For example, chicken and measles are more likely to be serious or fatal in sensitive children and adults who use corticosteroids. In children and adults who do not suffer from these diseases or are well immunized, special precautions should be taken to prevent the effects. It is not clear how the dose, route, and duration of corticosteroid administration affect the risk of disseminated infection. The contribution of prepared corticosteroid therapy to primary disease and/or risk is not yet generally known. Prevention with water coster shingles (VZIG) may be indicated with exposure to water cell shingles. Prophylaxis associated with intramuscular immunoglobulin (IG) may be indicated for measles exposure (see package leaflet for absolute information on Vzig and Ig).

Do not spray into eyes.

Precautions

In general

Nasal corticosteroids may cause decreased dosing in pediatric patients (see section) Occasional immediate hypersensitivity reactions or contact dermatitis may occur. Exceptional cases of creaky breathing, nasal septal perforation, cataracts, glaucoma, and dilated intraocular pressure have been reported after intranasal use of corticosteroids, including fluticasone propionate nasal spray, USP. fluticasone propionate Precautionary measures: pediatric use

Use of higher doses of corticosteroids may produce signs and symptoms and signs of depression of HPA function.

Systemic effects were smallest with appropriate doses of fluticasone propionate nasal spray, USP, but the risk may increase with huge doses. Therefore, it is recommended to ignore fluticasone propionate nasal spray USP in more appropriate doses.

Systemic corticosteroid effects, such as hypercortical or adrenal suppression, can be observed when used in people with greater than right dosage or with rare right dosage. If these configurations occur, the dose of Fluticasone Propionate Nasal Spray USP should be stopped slowly consistent with the accepted procedure for stopping oral corticosteroid therapy.

In a clinical study with fluticasone propionate Outbreaks of localized nose and throat infections caused by Intranasaal Albicans have occurred infrequently. When this infection does occur, it may require treatment with appropriate neighborhood therapy, and treatment with nasal sprays of fluticasone propionate should be stopped USP. Patients using fluticasone propionate nasal spray for more than a few months should be evaluated from time to time for indications regarding symptoms of Candida infection or other adverse reactions in the patient. the nasal mucosa. Candida

Nasal corticosteroids should be used with caution in patients with severe or stagnant TB airway infections. Untreated local or systemic fungal or bacterial infections; systemic viral or parasitic infections; or complicated herpes.

Because of the inhibitory effect of corticosteroids on wound healing in recently traumatized patients, it is not necessary to use corticosteroids to heal the wound. nasal septal ulcers, nasal surgery, or nasal There has been trauma; you do not need a nasal use corticosteroids until healing occurs.

Patient Information

Patients receiving Fluticasone Propionate Nasal Spray, USP should receive the correct information and package leaflet. This information is intended to assist in the safe and effective use of this medication. This is not an announcement of all possible or suspected side effects.

Patients should be warned to avoid the consequences of chicken po or measles and to consult a physician immediately if suffering from it.

Patients should apply nasal spray USP of fluticasone propionate with systematic intervals for reasonable effect. In some patients (12 years and older) with seasonal allergic rhinitis, then use of 200 mcg per day is effective and can continue to control symptoms as needed (see Table 1). Clinical Examination

A decrease in nasal Symptoms probably occur 12 hours after initiation of fluticasone propionate nasal spray, USP. Results of various clinical studies show statistically significant improvement on day 1 or 2 of treatment. However, only after several days of treatment may the absolute superiority of Fluticasone Propionate Nasal Spray USP be reached. Patients are not obligated to increase the prescribed dosage, but are obligated to contact their physician if symptoms do not improve or if the situation worsens.

In order to use Fluticasone Propionate Nasospray, USP correctly and achieve maximum improvement, the patient is obligated to carefully read and follow the instructions of the person who administered it.

Drug Interactions

Fluticasone propionate Substrate for cytochrome P450 3A4. Drug interaction studies with fluticasone propionate aqueous nasal spray Healthy Articles shows that ritonavir (a very effective cytochrome P450 3A4 inhibitor) can significantly increase plasma cortisol levels. fluticasone propionate Exposure leads to a significant decrease in serum cortisol levels (cf.) During postmarketing use, clinically significant drug interactions were reported. fluticasone propionate ritonavir actually cause systemic corticosteroid effects such as Cushing’s syndrome and adrenal suppression. Concurrent administration of of fluticasone propionate ritonavir is not recommended unless the potential for patient benefit outweighs the risk of systemic side effects of corticosteroids. Clinical Pharmacology: Drug Interactions

In a placebo-controlled mating study with 8 healthy volunteers, and one oral inhalation fluticasone propionate (1000 µg; 5 times the maximum daily dose) lasting several times ketoconazole (200 mg) produced a plasma structural fluticasone propionate inaccessibility of the effect, a decrease in the AUC of plasma cortisol, and an effect on urinary ecortisol excretion. Along with ketoconazole and other common potent cytochrome P450 3A4 inhibitors, fluticasone – propionate nasal spray, USP is carefully followed.

Carcinogenesis, mutagenesis, and fertility non-compliance

Fluticasone propionate No evidence of carcinogenic potential in mice during oral administration of up to 1000 µg/kg (not shown to exceed approximately 10 above the very maximum recommended daily intranasal dose in adult mice and the very adequate daily intravitreal dose in mice based on MCG/m)78 months or up to 57 µg/kg inhalation dose in rats (approximately twice the highly recommended daily highly recommended daily intranasal dose in adult subjects, and approximately equal to the highly maximum recommended daily intranasal dose in MCG/M – based test subjects at 104 months).2 2

Fluticasone propionate No genetic mutations were induced in prokaryotic or eukaryotic cells in vitro; no significant blastomere effects were observed in cultured human peripheral lymphocytes or mouse micronucleus tests in vitro.

No evidence of reduced fertility was observed in male and female female reproduction studies at subcutaneous doses up to 50 µg/kg (approximately twice the maximum recommended daily intranasal dose for adults based on MCG/m). Prostate authorities saw a considerable reduction at the 50 mcg/kg subcutaneous dose.2

Pregnancy

Teratogenic Effects

Pregnancy category C. Subcutaneous studies in mice and rats at doses of 45 and 100 µg/kg (about four times the highest recommended daily adult daily intranasal dose in terms of µg/m) show fetal toxicity that is characteristic of strong corticosteroidosis, compounds including delayed fetal ascending, corneal, split palate, and compounds containing a delayed bonus in the skull.2

In rabbits, subcutaneous doses of 4 µg/kg (less than the highest appropriate daily intranasal dose for adults) on the µg/m base were associated with fetal weight loss and split mouth development.2

However, no teratogenic effects have been reported with oral doses up to 300 µg/kg. of fluticasone propionate to the rabbit. No fluticasone propionate In this study, they were seen in plasma. This is consistent with the reported low bioavailability after administration via the oral route (see).2 Clinical Pharmacology

Fluticasone propionate Placenta was passed after oral administration of 100 µg/kg rat and 300 µg/kg rabbit (according to this maximum appropriate daily intranasal dose in adults based on µg/m, approximately 4 and 25).2

No adequate and appropriately controlled studies have been conducted in pregnant women. Fluticasone. propionate may only be used during pregnancy if the possible fetal risk may justify it.

Experience with the use of oral corticosteroids since their introduction in pharmacological rather than physical doses suggests that mice are more sensitive to the teratogenic effects of corticosteroids than people. Because corticosteroid production naturally increases during pregnancy, most women require lower doses of exogenous corticosteroids and little corticosteroid treatment is needed during pregnancy.

Breastfeeding mothers.

It is not known or fluticasone propionate excreted in breast milk. However, other corticosteroids have been identified in breast milk. 10 µg/kg tritheate administered subcutaneously to lactating rats. fluticasone propionate (less than the highest daily intranasal dose per µg/m) resulted in measurable radioactivity in milk. This is because there are no data from controlled studies on the use of intranasal administration. fluticasone propionate Breastfeeding mothers are advised to exercise caution in administering nasal sprays of fluticasone propionate to nursing women.2

Pediatric Administration

Fifty of 600 (650) patients between the ages of 12 to 17 years (4 to 11 years) and 440 patients were studied in a U.S. clinical study with fluticasone propionate insul spray, USP The safety and efficacy of fluticasone propionate nasal spray, USP in children younger than 4 years has not been investigated in children under 4 years of age.

Controlled clinical studies have shown that nasal corticosteroids may cause a reduction in the rate of ascent in pediatric patients. This effect was observed in laboratory studies of HPA axis depression. This suggests that elevation velocity is a more sensitive indicator of the systemic effects of corticosteroids in pediatric patients than studies commonly used as a function This long-term effect of this elevation velocity related to nasal corticosteroids, including its effect on final ripe length, has not yet been established. The possibility of “catching up” after cessation of treatment with nasal corticosteroids has not been properly investigated. Increases in pediatric patients treated with nasal corticosteroids such as fluticasone propionate spray, USP should be checked periodically (by stadiometry) on a regular basis. The impact of increased healing in the long term should be compared to the clinical advantages of healing and the risks/benefits of healing options. To minimize the systemic effects of nasal corticosteroids such as fluticasone propionate nasal spray, all patients should be titrated to the lowest dose that effectively keeps symptoms under control.

A 1-year placebo-controlled clinical lift study was conducted in 150 pediatric patients (3-9 years of age). (MCG at growth, approved dose limit) Growth (single daily dose 200 mcg, approved dose limit) Growth (single daily dose 200 mcg, approved dose Slimyte) (single dose 200 mcg, approved dose Rimieto) The primary population field of 56 patients who received fluticasone propionate nose spray USP and 56 patients who received placebo had a point estimate of growth rate lower fluticasone propionate nose spray USP 0, 14 cm/year than placebo (95% confidence interval interval interval. 0, 54 cm lower. Subsequently, placebo was up to 27 cm/year higher than placebo). Thus, compared to placebo, no statistically important effect was seen on ridge; no substantial evidence of HPA-as dysfunction or clinically important changes in bone mineral density was observed, as evidenced by 12-hour urine excretion and dual energy x-ray absorption support.

It cannot be excluded that fluticasone propionate nasal spray, USP may cause increased inhibition in sensitive patients.

elderly patients (n = 129)

A limited number of patients over 65 years of age (n = 129) or over 75 years of age (n = 11) are treated with fluticasone propionate nasal spray, USP in the United States. However, the number of patients was very inadequate for another study of surgery and safety, and the side effects reported in this population were comparable to those reported in younger patients.

Side Effects

To report a suspected side effect, contact Hi-Tech Pharmacal Co., Inc. at 1-800-262-9010 or 1-800-FDA-1088 or use FDA at www. FDA. Gov/Medwatch.

In a controlled American study, more than 3300 patients with seasonal allergies, long-term allergies, or long-term nonallergic rhinitis were treated with nasal medicine. fluticasone propionate In general, adverse effects in clinical studies were associated with skin irritation. the nasal mucous membranes and adverse effects were reported with nearly equal frequency by patients treated with the carrier. Claims generally did not lead to healing. Fewer than 2% of patients in clinical studies were terminated as a result of unnecessary incidents. This percentage was comparable with placebowags and intensive comparators.

No systemic corticosteroid side effects were reported during up to six months of controlled clinical testing with Fruticasone Neissaerosol, USP. However, if the recommended limits are exceeded, or if a person is more sensitive or fluticasone propionate spray used in combination with other corticosteroids, signs of hyperdermatism such as Cushing’s syndrome may occur There is a possibility of

The following incidence of common adverse reactions (>3%, where incidence in fluticasone (Study subjects with propionate coatings perform better than placebo), 7 controlled in which 536 patients (57 girls and 108 boys aged 4-11 years, 137 women and 234 young adults and adult men) were treated with nasal fluticasone propionate nas Based on clinical studies. Spray, USP, 200), MCG once daily for 2 to 4 months, 246 patients (119 women and 127 young adults and adult males) were treated with 200 MCG, fluticasone propionate insular spray, once daily for 6 months. This table includes extra data from two studies, in which 167 children (45 girls and 122 boys aged 4-11 years) received fluticasone propionate nasospray, USP, 100 mcg once daily.

FluticasonPropionate Nasal Spray, USP

100 mcg once daily

FluticasonPropionate Nasal Spray, USP

200 mcg once daily

Other side effects that occurred in less than 3% of patients but more frequently in more than 1% of patients fluticasone propionate (uncertain relationship to treatment) Integration: blood in nasal mucus, runny nose, abdominal pain, diarrhea, fever, flu-like symptoms, pain, dizziness, bronchitis.

Observed during medical

Practice: in addition to the unwanted symptoms reported from the clinical examination, appropriate action has been observed during the use of nasal fluticasone propionate Medical Practice. They are reported spontaneously from an unknown amount of the population, so it is not possible to create frequency estimates. These actions were chosen for hospitalization because of their thoroughness, frequency, or causal context reporting to fluticasone propionate or a combination of these points.

In general

hypersensitivity reactions, including angioedema, skin rash, facial and tongue edema, dental ame, ur measles, bronchospasm, creaky breathing, dermatosis, and anaphylaxis/anaphylactoid reactions were rarely mild.

Ear, mouth, and throat

Alteration or loss of taste or flavor, and sometimes, nasal Septail perforation, nasal Swearing, sore throat, throat complaints and dryness, coughing, ho, voice constructs.

Dryness and dissatisfaction, conjunctivitis, blurred vision, glaucoma, fertilized intraocular pressure, cataracts. Cases of elevated suppression have been reported for nasal corticosteroids, at doses of fluticasone nasal spray, USP (see). Precautionary measures: pediatric use

Overdose.

Chronic overdose may lead to signs/symptoms of hypercortisolism (see ) 2 mg intranasal (10 to 1 above recommended dose) of fluticasone propionate 7 days healthy human volunteers tolerated twice daily A single oral dose of up to 16 mg has been investigated in human volunteers with no acute toxic effects. With human volunteers repeated oral doses of up to 80 mg per day for 10 days and oral doses up to 10 mg per day for 14 days have been repeated in patients. There were few or no problems with side effects, and confrontations were comparable in the intensive placebo group. An acute overdose at this dose is virtually impossible because one bottle of fluticasone propionate spray (USP) contains an estimated 8 mg. of fluticasone propionate . PRECAUTIONS

The oral and subcutaneous median lethal doses in mice and rats were >1,000 mg/kg (>20,000 and >41,000 times, respectively, the maximum recommended daily intranasal dose in adults and >10,000 and >(20, 000 A accordingly, the very maximum daily intranasal dosage for a boy on a Mg/M basis).

Dosing and administration

Patients should apply nasal sprays of fluticasone propionate (USP) at systematic intervals to achieve reasonable efficacy.

Adults

Recommended starting dose IS 2 sprays (50 mcg of fluticasone propionate each once a day in the nostrils (total daily dose, 200 mcg); the same exclusive dose, shared at 100 mcg, is given twice a day (8 am in the morning, 8 pm in the evening). After the first few days, the patient has the opportunity to lower the dose to 100 mcg. (1 spray After the first few days, the patient may lower the dose to 100 mcg once a day, per nostril, for maintenance therapy. Some patients with seasonal allergic rhinitis (12 years and older) may find that use of 200 mcg per day, if needed, is effective in controlling symptoms (see below). Better symptom control can be achieved with planned serial dosing. Adult Clinical Studies

Adolescents and young children (ages 4 and up)

Patients should start with 100 mcg (1 spray (daily in all nostrils). patients who do not respond adequately to 100 mcg have every chance of 200 mcg (2 sprays (all nostrils). After proper control is reached, the dose should be reduced to 100 mcg (1 spray (all nostrils) per day.

The maximum total daily dose may not be exceeded 2 sprays All nostrils (200 mcg/day). (See also.) Clinical studies: dose individualization

Fluticasonpropionate Nasal Spray, USP is not recommended for children under 4 years of age.

Instructions for Use

Illustrated leaflet guide Fluticasone Propionate Nasal Spray, USP Coagulation for Troublesome Use.

Instructions for Use

Read this leaflet carefully before you start taking your medication. It will give you concise information about your medicine. For more information, contact your doctor or pharmacist.

What you should know about rhinitis

Rhinitis is a text that refers to inflammation of the mucous membranes of the nose. If you are suffering from linititis, your mouthful of watery stuff will be your beak. Rhinitis can make your beak itchy and you sneeze. Rhinitis can be caused by allergies to pollen, animals, fungi, or other substances. It may also have non-allergic criteria.

Do you owe it to the nobility about fluticasone propionate nasal spray, USP

Your doctor has declared fluticasone propionate spray USP as a medication that can help treat rhinitis. Fluticasone Propionate Nasal Spray, USP contains fluticasone propionate What are considered synthetic corticosteroids. Corticosteroids are natural drugs that occur in the body and help fight inflammation. When. you spray Fluticasone Propionate Nasal Spray, USP brings nasal It helps to suppress the signs of allergic reactions and the stuffing, walking, itching, sneezing that bothers you so much.

Things to Remember About Fluticasone Propionate Nasospray, USP

1. shake carefully before use.

2. Use your nasal spray As prescribed by your doctor. Instructions are on the pharmacy label.

3. Keep your nasal spray 2. Keep out of reach of children.

USP For nasal spray.

• If you are pregnant (or want to become pregnant),
• If you are breastfeeding your baby,
• If you are allergic to fluticasone propionate nasal spray, USP, etc. nasal corticosteroid,
• if you use medicines containing ritonavir (often used to treat HIV infection or AIDS).

In some cases, this medication will not work and your doctor may prescribe another medication. Make sure your doctor knows what other medications you will be using. Tell your doctor before using this medication.

Use of nasal sprays

• Follow the instructions for the remainder of this leaflet. Tell your doctor or pharmacist if you are experiencing problems.
• It is important that you use the product exactly as prescribed by your doctor. The pharmacist’s label usually states how much you must take and how often. If not, or if you are unsure, ask your doctor or pharmacist.

Dosage.

• The usual starting dose is for. Sometimes your doctor can advise that 1 spray twice a day (in the morning and in the evening) in one of the two nostrils. The total dosage is not more than one step 2 sprays Apply daily in one of the two nostrils. Then you will experience yourself more than others, 1 spray There is to be enough in all nostrils every day. Adult 2 sprays Once daily in one of the two nostrils

For children (from age 4), the usual starting dose is 0.5 liters. Sometimes your doctor may recommend it 2 sprays use daily in one of the two nostrils. Then, if you begin to feel better than the other one, 1 spray one of the two nostrils daily may be enough. Youngsters and children 1 spray Once daily in one of the two nostrils

How to use the nasal spray

Read directions carefully and use only as indicated.

To use

1. shake bottle carefully and remove cap (Figure 1).

2. if using for the first time or if not used for more than one week, the pump must be filled with air. To compensate for the pump, hold the bottle as shown in the image. the nasal Deny the applicator with your index and middle fingers on either side of you. the nasal Press the applicator under the bottle and thumb.1 At a time, press pump 6 and let go again (Figure 2). The pump is now ready for use. If the pump has not been used for 7 days, you will need to prime the pump until a penalty occurs. spray appears.

Use of spray

3. cut off the nose and clean the nostrils.

4. close one nostril. Tilt head slightly forward and apply the bottle carefully, keeping it vertical. the nasal Insert the applicator into the other nostril (Figure 3). 5.

5. begin to blow your nose, inhale strongly, and push the applicator down to expel the air. the spray For field absolute effect, use index and middle fingers. to spray Support the bottom of the bottle with your thumb. Be careful not to get the spray in your eyes. Breathe in slowly through the nostrils (Figure 4). 6.

Exhale through the mouth.

7. If a second spray Repeat steps 4-6 if you need to blow into a specific nostril. 8.

Repeat steps 4-7 for the other nostril. 9.

9. Wipe the nasal Replace applicator with a clean cloth and attach lid (Figure 5). 10.

Do not use this bottle more than the amount indicated on the label. of sprays Although the bottle is not completely empty. Before discarding the bottle, consult your physician to determine if you need to take it again. Do not take additional doses or discontinue use of Fluticasone Propionate Nasal Spray (USP) without consulting a physician.

Cleaning

Your nasal spray The area should be cleaned at least once a week. Arrange this: 1.

1. remove the lid by pulling it slowly upward. 2. the nasal applicator.

2. wash the applicator and cap in warm tap water. Allow to dry at room temperature and return the applicator and cap to the bottle.

3. If the nasal The applicator is lockable and can be sent as described above and forgotten to soak in warm water. Rinse with cold tap water and allow to dry before reapplying. Do not attempt to unlock the applicator! the nasal Insert a pin or other sharp object to unlock the applicator.

Store nasal drops

• Keep Personal Fluticasone Propionate Nasal Spray (USP) out of the reach of children.
• Do not spray into eyes.
• Store at 4° to 30°C (39°F to 86°F).
• Do not use Fluticasone Personal Nasal Spray (USP) after the expiration date on the label and box.

Remember: This medicine has been prescribed by a physician. Do not give this medication to anyone else.

For more information.

The package leaflet does not contain complete information about the medication. If you have any questions or concerns, ask your doctor or pharmacist.

Read this leaflet carefully again. Do not throw it away until you have finished taking the medicine.

About Us

Family Medicine

In 2024 our team of doctors and nurses provide a comprehensive range of family planning services. Our doctors have expertise in antenatal care, preconception planning, and STD checks. Contraceptive advice including Mirena and Implanon insertion is available.

• Early detection of illness;
• Family planning;
• Promotion of healthy lifestyle;
• Skin cancer checks;
• Sports injuries;
• Weight reduction;
• Workers compensation and third party.

---

Children's Health

Baby Weighing Service. Babies can be booked with our Nurse for weighing, a doctors appointment is not required to use this service. Contact reception for a appointment to have your baby weighed.

Immunisations. At Tuggeranong Square children's immunisation is regarded an important part of your childs health care. Our doctors take immunising children very seriously. and to ensure all children are immunised Tuggeranong Square Medical Practice doctors BULK BILL for all childhood immunisations. Tuggeranong Square Medical Practice also ensures the Practice Nursing Staff are highly trained in childhood immunisations.

---

Women's Health

Our practice is dedicated to treating a wide spectrum of women’s health concerns. We offer pre-natal, antenatal and postnatal care, contraceptive options, pap screening, and preventative health care advice. We provide assistance, advice and support through all stages of life, recognising the many issues many women may face from adolescence through to the peri and post-menopausal period.

• Cervical Screening tests;
• Reproductive health. Including Mirena and Implanon insertion;
• Shared antenatal care.

---

Men's Health

We encourage men to present routinely to their GP to discuss all aspects of their health. We provide comprehensive advice and support for men to address the prevention and management of various health conditions. This may include assessments for cardiovascular risk, diabetes, cancer prevention, mental health assessments, STD screening, sports injuries and the importance of sleep as it relates to other areas of health.



• Preventative Healthcare. Including cardiovascular screening, mental health and cancer checks;
• Prostate examination.